- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Scott Hewitt Describes the Ongoing Shift to Value-Based Arrangements
While not every doctor is successful in value-based contracts, there is a shift in the right direction to more value-based care, explained Scott Hewitt, vice president, payment strategy and innovation, UnitedHealthcare.
While not every doctor is successful in value-based contracts, there is a shift in the right direction to more value-based care, explained Scott Hewitt, vice president, payment strategy and innovation, UnitedHealthcare.
Transcript
How have UnitedHealthcare’s value-based care contracts been improving?
So, we have a plethora of information or data points that we can look at, whether it’s reduced inpatient days, reduced [emergency room] use, increased [primary care physician] visits, lower specialty visits per 1000, but it’s more than just utilization metrics, it’s also quality metrics and when we look at quality metrics we’re seeing our providers are in a value-based contracting arrangement. So, it doesn’t necessarily need to be an [accountable care organization] but that they’re focused on and improving the care that members are receiving.
So, it might be lowering C-section rates, it might be focused on appropriate use of lab services, it might be prescription drug use or generic drug use, tier one drug use. There’s lots of different measures that we look at it at UnitedHealthcare and while not every provider is successful in these arrangements, if I look at my entire book of business, I am seeing the shift in the right direction.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More
